RARE-51. RITUXIMAB, METHOTREXATE, BCNU, ETOPOSIDE, AND PREDNISONE (RMBVP) FOR THE TREATMENT OF RELAPSED/RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE SINGLE CE...

Autor Reiss, Samantha, Yerram, Prakirthi, Modelevsky, Lisa, Grommes, Christian
Vydáno v Neuro Oncol (2019)

Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas

Autor Reiss, Samantha N., Yerram, Prakirthi, Modelevsky, Lisa, Grommes, Christian
Vydáno v J Immunother Cancer (2017)

ACTR-94. TOXICITY OF SINGLE AGENT CARMUSTINE VERSUS CARMUSTINE PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT OR PROGRESSIVE HIGH GRADE GLIOMAS

Autor Yerram, Prakirthi, Reiss, Samantha, Modelevsky, Lisa, Gavrilovic, Igor, Kaley, Thomas
Vydáno v Neuro Oncol (2017)

Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas

Autor Yerram, Prakirthi, Reiss, Samantha N, Modelevsky, Lisa, Gavrilovic, Igor T, Kaley, Thomas
Vydáno v J Neurooncol (2019)

Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma

Autor Modelevsky, Lisa, Tizon, Richard, Reiss, Samantha N, Smith, Marcel, Garonce, Rachel, Kaley, Thomas
Vydáno v CNS Oncol (2018)

Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City

Autor Yerram, Prakirthi, Thackray, Jennifer, Modelevsky, Lisa R, Land, Josiah D, Reiss, Samantha N, Spatz, Krisoula H, Levoir, Andrea C, Pak, Terry K, Dao, Phuong H, Buege, Michael J, Derespiris, Lauren M, Lau, Carmen, Orozco, Jennifer S, Boparai, Manpreet, Koranteng, Lauren A, Reichert, Kate E, Yan, Shirley Q, Daukshus, Nicole P, Mathew, Sherry, Buie, Larry W, Tizon, Richard F, Freeswick, Scott, Liu, Dazhi, Harnicar, Stephen
Vydáno v J Oncol Pharm Pract (2021)